PDA Technical Report 82 (TR 82), "Low Endotoxin Recovery," provides a crucial, internationally recognized framework for managing endotoxin masking in biologic drugs, specifically guiding Hold Time Studies. The 2019 report addresses how formulation components, such as surfactants, can inhibit LAL test detection, with active industry discussions ongoing regarding a future revision. For more details on the upcoming workshop, visit Parenteral Drug Association PDA Pharmaceutical Manufacturing & Quality Conference 2025
Hold Time Studies (HTS): Essential for demonstrating the absence of LER in all BLA submissions containing surfactants.
C. Biofilm Considerations
A significant portion of the report addresses the risk of biofilm.
Step 1: Risk Assessment Before implementing, a formal risk assessment (e.g., FMEA – Failure Mode and Effects Analysis) must be conducted to identify potential failure points, such as cold spots, dead legs, or pump overheating due to low flow.
In the quiet, sterile labs of biopharmaceutical manufacturing, a mystery once baffled scientists: the "vanishing" endotoxin. This is the story of Low Endotoxin Recovery (LER) and the guide created to solve it PDA Technical Report 82 The Invisible Threat
4. Validation and Implementation Strategy
TR 82 outlines a structured approach to validating a trickle sterilization process. This is the "how-to" section of the document and is critical for Quality Assurance and Validation teams.